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Abstract
Infections with influenza A viruses (IAV) are still amongst the major causes of highly contagious severe respiratory diseases
not only bearing a devastating effect to human health, but also significantly impact the economy. Besides vaccination that
represents the best option to protect from IAV infections, only two classes of anti-influenza drugs, inhibitors of the M2 ion
channel and the neuraminidase, often causing resistant IAV variants have been approved. That is why the need for effective
and amply available antivirals against IAV is of high priority. Here we introduce LADANIA067 from the leaves of the wild
black currant (Ribes nigrum folium) as a potent compound against IAV infections in vitro and in vivo. LADANIA067 treatment
resulted in a reduction of progeny virus titers in cell cultures infected with prototype avian and human influenza virus
strains of different subtypes. At the effective dose of 100 mg/ml the extract did not exhibit apparent harming effects on cell
viability, metabolism or proliferation. Further, viruses showed no tendency to develop resistance to LADANIA067 when
compared to amantadine that resulted in the generation of resistant variants after only a few passages. On a molecular basis
the protective effect of LADANIA067 appears to be mainly due to interference with virus internalisation. In the mouse
infection model LADANIA067 treatment reduces progeny virus titers in the lung upon intranasal application. In conclusion,
an extract from the leaves of the wild black currant might be a promising source for the development of new antiviral
compounds to fight IAV infections.
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Introduction
Influenza A viruses (IAV), family members of the genera
Orthomyxoviridae, are characterised by a negative oriented, seg-
mented single strand RNA genome. Although the natural reservoir
of these viruses is within wild living waterfowl, IAV also infect
humans and several animal species [1]. As a common cause of
highly contagious severe respiratory diseases in humans IAV
mainly affect the upper respiratory tract, such as the nose, throat
and bronchi [1]. Infections are characterised by the sudden onset
of fever, sore throat, headache, severe malaise, muscle pain and
nasal inflammation. Thus, IAV not only cause a devastating effect
to human health, but also significantly impact the economy.
Besides seasonal outbreaks, IAV bear the potential for the
development of new pathogenic IAV. The continuous and rapid
emergency of new highly pathogenic avian influenza virus
(HPAIV) of the H5N1 type, transmitting from poultry to human,
and the recent pandemic H1N1v IAV outbreak, to which no
vaccines had been amply available in time, highlight the urgent
need of effective antivirals to fight influenza viruses. Although,
vaccination is the best option to protect from IAV infection, time-
consuming generation processes limit its ample availability.
Currently two classes of antivirals that either target the M2
protein (amantadine, rimantadine) or the neuraminidase (NA)
(oseltamivir, zanamivir) of IAV are available. Unfortunately these
compounds are characterised by rapid resistance development.
Most H3N2 viruses and human isolates of H5N1 viruses are
already resistant to M2-blockers, and an increasing incidence of
resistance development against NA-blockers has been reported
[2,3,4,5]. While swine-origin influenza viruses (S-OIV) are
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completely resistant to the adamantanes, interestingly several S-
OIV of the 2009 pandemic exhibit also natural resistance to NA-
blockers [6,7], thus bearing potential for multidrug-resistant
influenza viruses [8]. Due to the obvious need for new and amply
available antiviral agents that do not show any tendency to cause
toxic side effects or generate resistant virus variants, the use of
plant-derived extracts or compounds received increasing attention.
Although various studies have demonstrated the antiviral potential
of plant-derived compounds in cell culture, studies that explore
their molecular mode of action or their activity in vivo are still
scarce.
Regarding the active ingredients of plant extracts, a significant
antiviral potential has been demonstrated for the group of
polyphenols [9]. With more than 8000 phenolic structures, these
substances are widely distributed in the plant kingdom. However
marginal knowledge on absorption, bio-distribution and metabo-
lism of polyphenols is available. While small polyphenols are
absorbed by cells and exhibit antioxidative functions, polymeric
polyphenols are only poorly absorbed or metabolized. Numerous
studies indicate an antiviral or antibacterial function of polyphe-
nolic substances [9] and antiviral activity against influenza virus
infection has been demonstrated in vitro and in vivo [10,11].
Recently, CYSTUS052, a polyphenolic substance derived of
Cistus incanus spp. tauricus has been functionally characterised in
context of influenza virus infections. CYSTUS052 directly
interferes with the virus particles and thereby blocks virus
attachment in a non-specific manner [10,11]. At the same time
cells appear to be inert against the action of the extract ingredients,
presumably due to the fact that the active compounds are too big
to enter cells and get metabolized. Furthermore, a rather
unspecific coverage of the virions themselves lowers the risk of
new emerging resistant virus variants. Finally, the effectiveness of
this extract against respiratory infections has been already tested in
a prospective, randomised, placebo-controlled clinical trial in
human patients [12].
Here we focussed on another polyphenol-rich plant, Ribes nigrum
folium that exhibits broad curative properties [9,13,14,15,16,17].
Within the present study we investigated the anti-influenza virus
activity of LADANIA067 that is an extract made from the leaves
of a wild form of Ribes nigrum (black currant). The plant is
cultivated but also grows in the wild across central and eastern
Europe. It is part of the shrub layer in the level and hill country.
Ribes nigrum folium is rich in phenolic acids, flavonoids and
carotenoids [18]. Furthermore, Ribes nigrum folium also contain
high amounts of Proanthocyanidins, especially Prodelphinidins,
and ascorbic acid [19]. Until today antiviral and antibacterial
properties of Ribes nigrum fruits, which were used in the past as juice
against the common cold, have been described [15]. The yield of
anti-oxidants has been shown to be higher in the leaves than in the
berries [18]. Our results revealed a potent antiviral activity of
LADANIA067 against IAV in vitro and in vivo without toxic effects
or tendency to induce viral resistance.
Materials and Methods
Plant Extracts
LADANIA067 Extract Charge-Numbers: #10/17; 020709/
069; 180510/158; 150211/281; 140113/523; 140113/524 and
CYSTUS052 #080110/095 were supplied and originally devel-
oped by Dr. Pandalis NatUrprodukte GmbH & Co. KG
(Glandorf, Germany). The reference extract CYSTUS052 is a
preparation of Cistus incanus spp. tauricus as described in [10,11].
LADANIA067 is a preparation from the leaves of a wild form of
Ribes nigrum (black currant). LADANIA067 was delivered in
solution and was solved in sterile cell culture medium from 10 to
200 mg/ml and added directly to the medium or virus-stock.
Viruses, Cells and Viral Infections
Avian influenza virus A/FPV/Bratislava/79 (FPV) (H7N7),
recombinant human influenza virus A/Puerto Rico/8/34 (PR8)
(H1N1rec) and pandemic swine origin human influenza virus (S-
OIV) A/Nordrhein-Wesfalen/173/2009 (H1N1pan), harboring
the oseltamivir resistance mutation NA (H275Y) [20], have been
propagated and passaged in Madin Darby canine kidney (MDCK)
cells. A prototype isolate of human influenza virus A/Puerto Rico/
8/34 (PR8) (H1N1) was grown in 10-days-old embryonated
chicken eggs. After incubation at 37uC for 2 days the allantois fluid
was harvested and used for infection as described below [21].
For infection cells were washed in PBS, incubated with virus
diluted in PBS/BA (PBS containing 0.2% BSA, 1 mM MgCl2,
0.9 mM CaCl2, 100 U/ml penicillin and 0.1 mg/ml streptomy-
cin) for 30 min at 37uC at the indicated multiplicities of infection
(MOI). The inoculum was aspirated and cells were incubated with
MEM or DMEM containing 0.2% BSA, 1 mM MgCl2, 0.9 mM
CaCl2 and antibiotics. In the case of infection with H1N1,
H1N1rec or H1N1pan medium was supplemented with 2 mg/ml
trypsin. MDCK cells were grown in MEM and the human lung
epithelial cell line A549 was grown in DMEM, respectively. All
media were supplemented with 10% heat-inactivated fetal bovine
serum (FBS). For pro-apoptotic or pro-inflammatory stimulation
of cells Staurosporine (Sigma) (1 mM, 4 h or 8 h), TNFa (Sigma)
(5 ng/ml, 20 min), or human recombinant EGF (R&D systems
Minneapolis, USA) (30 ng/ml, 5 min) were directly added into the
medium.
Plaque Titrations and Resistance Assays
Supernatants, collected at the indicated time points, were used
to assess the number of infectious particles (plaque titers) in the
sample. Briefly, MDCK cells grown to 90% confluence in 6-well
dishes were washed with PBS and infected with serial dilutions of
the supernatants in PBS/BA for 30 min at 37uC. The inoculum
was aspirated and cells were incubated with MEM/BA (medium
containing 0.2% BSA and antibiotics) supplemented with 0.6%
Agar (Oxoid), 0.3%DEAE-Dextran (Pharmacia Biotech) and 1.5%
NaHCO3 at 37uC, 5%CO2 for 2–3 days. Virus plaques were
visualized by staining with neutral red. The virus titers are
presented as plaque-forming units per ml (pfu/ml). Generation of
resistant virus variants to antiviral treatment was assessed. Briefly
A549 cells were infected with the influenza A virus strain FPV
(MOI= 0.001) and were left untreated or treated with the
indicated amounts of LADANIA067. Unless otherwise indicated
cells and viruses were pre-incubated with LADANIA067 for
30 min and LADANIA067 has been further added to the medium
throughout the infection. To evaluate the resistance development
24 h post infection (p.i.) supernatants were taken and used for a
second infection round. This procedure was repeated for several
subsequent passages. As a reference antiviral compound cells have
been treated with amantadine (Sigma) (5 mM) that is know to
induce IAV resistance quite rapidly. Supernatants were assayed for
progeny virus yields by standard plaque titrations. Virus yields of
mock-treated cells were arbitrarily set as 100%.
MTT-cell Proliferation Assay
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
liumbromide] assay is based on an enzymatic reaction of the
mitochondrial succinic dehydrogenase. In viable and proliferating
cells these enzyme cleaves the tetrazolium rings of the pale yellow
MTT which results in formation of dark blue formazan that is
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largely impermeable to cell membranes and therefore accumulates
in healthy cells. The amount of formed formazan can be measured
in a colorimetric assay at OD 562 nm and is directly proportional
to the number of proliferating cells. A549 cells were left untreated
or treated with the indicated amounts of LADANIA067 for
different time periods. Afterwards cells were washed with PBS and
incubated with MTT (5 mg/ml) for 3 hours at 37uC. Reaction was
blocked by DMSO (Sigma) and cells were further incubated for
20 min at 37uC. The colour reaction was measured in an Emax
precision microplate reader at 562 nm. The untreated control was
arbitrarily set as 100%.
Plasmids, Transient Transfection and Reporter Gene
Assay
A constitutive active CMV promoter luciferase plasmid was
transfected with Lipofectamine 2000 (Invitrogen) into A549 cells
according to a protocol by Basler et al. [22]. Eight hours post
transfection cells were left untreated or treated with the indicated
amounts of LADANIA067 or 10 mg/ml Cycloheximide (Bio-
Trend) for 18 hours. Subsequently cells were harvested with
200 ml lysis buffer [50 mM Na-MES, pH 7.8, 50 mM Tris-HCl,
pH 7.8, 10 mM dithiothreitol (DTT) and 2% Triton X-100].
Luciferase activity was measured and given as relative fold
activation 6SD of nine samples as the ratio of luciferase activity
relative to the DMSO control.
Flow Cytometry Analysis
A549cellswere left untreatedor treatedwithLADANIA067of the
amounts and for times indicated. Cells were washed with PBS,
trypsinized, washed again and resuspended in PBS containing
propidium iodide (PI) in a concentration of 50 mg/ml. After
incubation for 1 h at room temperature (RT) PI was removed by
washing cells with PBS and fluorescence was determined in the FL2-
channel (585 nm) using a FACScalibur cytometer (Becton Dick-
inson).Aspositive controlA549cellswere treatedwithStaurosporine
(1 mM) and EDTA (5 mM) for 4 h and analysed as described above.
Western Blotting
ForWesternblots cellswere lysedon icewithRIPA lysis buffer (1%
(v/v) NP-40, 0.5% (v/v) DOC, 1% (w/v) SDS, 150 mM NaCl,
50 mM Tris pH 8, 90% H2O dest., 200 mM pefablock, 5 mg/ml
aprotinin, 5 mg/ml leupeptin, 1 mM sodium-vanadate, 5 mM
benzamidine) for 30 min. Cell lysates were cleared by centrifugation
and protein yields were estimated employing a protein dye reagent
(Bio-RadLaboratories). Equal amounts of proteinwere separated by
SDS-polyacrylamidegel electrophoresis and subsequentlyblottedon
nitrocellulose membranes. Anti-PARP monoclonal antiserum was
purchased from BD Transduction Laboratories. Antiserum against
the influenza virus protein M1 was obtained from ABSerotec.
Antisera against phosphospecific EGFR(Y1068), EGFR and phos-
phospecific ERK1/2 (pT202/pY204, pT185/pY187) were pur-
chased fromCellSignalingTechnology.Antiserumagainst IkBawas
purchased from Santa Cruz Biotechnologies. Loading controls were
performed with ERK2 antiserum (Santa Cruz Biotechnologies).
Protein bands were visualized in a standard enhanced chemilumi-
nescence reaction.
Hemagglutination-inhibition-test
Influenza viruses are characterised by their ability to agglutinate
erythrocytes. This hemagglutinating activity can be visualized
upon mixing virus dilutions with chicken erythrocytes in microtiter
plates. The chicken erythrocytes (Lensing-Baeumer, Ibbenbueren)
supplemented with 1.6% sodium citrate (Sigma) in sterile water
were separated by centrifugation (8006g, 10 min, room temper-
ature) and washed three times with sterile PBS (Invitrogen). The
lowest amount of virus particles able to agglutinate the chicken
erythrocytes was determined in a serial virus dilution and used to
investigate the inhibitory effect of LADANIA067 in comparison to
CYSTUS052 onto the hemagglutinating activity. Untreated
erythrocytes precipitate to the bottom of the plate, while upon
preincubation with virus the blood cells show an even and diffuse
distribution. Briefly, LADANIA067 and CYSTUS052 were
serially diluted as indicated. From virus stock (H7N7, 16109
pfu) 1/128 dilutions were made, and 50 ml/well of this virus
dilution was added as indicated. After preincubation of 45 min,
chicken erythrocytes (1/20 in PBS) were mixed with the solution.
Binding Analysis of LADANIA067 to Cellular Surface and
Indirect Immunofluorescence Microscopy
A549 cells were left untreated or treated with LADANIA067
(100 mg/ml) for 1 h at 37uC. Subsequently biotinylated Sambucus
nigra agglutinin (SNA) purchased from Linaris (Wertheim,
Germany), (1 mg/ml) was incubated for 1 h at 4uC with A549
cells. SNA recognizes a-2–6 Galactosidases, predominantly
present at the surface of A549 cells and responsible for IAV
binding of human species. Subsequently cells were incubated with
Cy3-conjugated streptavidin to detect lectins and were analysed in
fluorescence microscopy. Fluorescence was visualized using a
Axiovert 2000 ApoTome microscope with AxioCam digital
camera and AxioVision software (Zeiss). To monitor cell
morphology transmitted light microscopy was applied, using the
same equipment.
In vivo Experiments
All animal studies were performed in compliance with animal
welfare regulations (permission number Az 8.87–50.10.36.09.007
by the State Agency for Nature, Environment and Consumer
Protection [LANUV], Germany).
Eight-week-old BALB/c mice were obtained from the animal-
breeding facilities Harlan-Winkelmann. For infection, the animals
were anesthetized by intraperitoneal injection of 200 ml solution of
ketamine (Ceva) and xylazin (Ceva; equal amounts of 2% xylazin
solution and 10% ketamine solution were mixed 1:10 with PBS).
Mice were treated with LADANIA067 using the COAALA Mouse
Aerosol Application System (Activaero GmbH). The LADA-
NIA067 extract was dissolved in sterile H2O and stock solutions of
10 mg LADANIA067/ml and 15 mg LADANIA067/ml were
prepared. BALB/c mice were placed in the tube-cylinder and
exposed to 1.5 ml (per mouse), 2 bar of aerosolized LADANIA067
extract for 10 min twice a day for three (lung titer) or five days
(body weight). The control group was treated with the same
amount of H2O correspondingly. Mice were infected ten minutes
after the first exposure via the intranasal route with the influenza
virus strain A/FPV/Bratislava/79 (H7N7) (103 pfu) or the
recombinant influenza virus A/Puerto Rico/8/34 (H1N1rec)
(46102 pfu) in a 50 ml volume to determine the viral replication
in the lung or A/FPV/Bratislava/79 (H7N7) (56102 pfu) to
monitor the body weight. The general health status of the animals
was controlled twice a day and body weight was measured every
day. Due to protection of animal welfare restrictions, mice were
sacrificed upon a body weight loss of 20% at the utmost. For
determination of lung virus titer, mice lungs were collected in 3 ml
PBS at day 3 p.i. The samples were homogenized using a
FastPrep24 homogenizator (MP Biomedicals) with Lysing Matrix
D (MP Biomedicals). The samples were centrifuged at 10 000 rpm
for 10 min at 4uC. The supernatants were taken and assayed in
standard plaque analysis as described above.
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Results
LADANIA067 Inhibits Influenza A Virus Replication in a
Concentration Dependent Manner
In a first set of experiments we investigated whether
LADANIA067 exerts an antiviral effect against influenza A virus
(IAV) infection in cultured cells. Therefore, the commonly used
human alveolar type II epithelial cell line A549 was incubated with
LADANIA067 at various concentrations for 30 min before
infection and during the on-going infection process. Additionally,
the virus was pre-incubated with LADANIA067 at the various
concentrations for 30 min prior to infection (Fig. 1A–C). For
infection we used different IAV strains, including the highly
pathogenic avian H7N7 influenza virus A/FPV/Bratislava/79
(FPV) (Fig. 1A), an oseltamivir-resistant variant of swine-origin
H1N1 influenza virus, strain A/Nordrhein-Westfalen/173/09
(H1N1pan) (Fig. 1B) and the human H1N1 prototype isolate A/
Puerto-Rico/8/34 (PR8) (H1N1) (Fig. 1C). For all three viruses a
dose-dependent reduction of progeny virus titers was detected
upon LANDANIA067 treatment in single-cycle (8 h) and multi-
cycle (24 h, 32 h) experiments indicating a broad antiviral activity
towards different IAV strains.
LADANIA067 Treatment does not Affect Cell Morphology
and Viability and does not Negatively Interfere with
Cellular Proliferation and Metabolism
Since drug safety is a major issue for antiviral agents, we
analyzed whether antiviral acting concentrations of LADANIA067
would have any harming effect on healthy cells (Fig. 2A). Initially,
cells were treated with LADANIA067 (50 mg/ml and 100 mg/ml)
for different time periods (up to 72 h) and the morphology of
untreated or LADANIA067-treated cells was compared. No
difference in cell shape or cell numbers could be observed
(Fig. 2A). Further, MTT cell proliferation assays revealed similar
cell proliferation independent of the presence or absence of
LADANIA067 (Fig. 2B). Also, the observed reduction in progeny
virus titers was not due to a general inhibition of cellular
transcription and translation because constitutive expression of a
reporter gene (luciferase) driven by a constitutively active promoter
(CMV) was not affected by LADANIA067 treatment in contrast to
the Cycloheximide control (Fig. 2C). In a cytotoxicity assay, A549
cells were treated with LADANIA067 for different time periods
(up to 72 h) and were stained with propidium-iodide (PI) to
monitor cell death (Fig. 2D). Again, no significant changes in the
number of dead cells could be detected. In accordance with these
data, LADANIA067 did not induce apoptosis as evidenced by a
lack of cleavage of Poly-ADP-ribose-polymerase (PARP), a
prominent substrate of apoptotic caspases (Fig. 2E). In conclusion,
the extract did not show any significant harmful effects on cell
proliferation or cell survival, and did not alter transcription or
translation in this system.
An Early Step in the Infection Process is Blocked Upon
Treatment of Cells with LADANIA067
To determine the step in the IAV life cycle that is affected by
LADANIA067, supernatants from cells that were treated with
LADANIA067 at different time points pre- and post-infection were
analyzed for their contentofprogenyvirus (Fig.3). Interestingly,most
prominentreductionsofvirustiterswereobtainedwhentheinfectious
viruswaspretreatedwithLADANIA067,whereaseffectswere far less
pronouncedwhenLADANIA067was added exclusively to cells pre-
or post-infection.
The earliest event during the infection cycle is virus binding to
sialic-acid residues at the cellular surface. To analyse whether
LADANIA067 may interfere with sialic-acids of cellular surface-
proteins and thus prevents viral attachment, we made use of lectin
binding assays. Lectins bind sialic acids in a multivalent fashion and
causehemagglutination similar to IAV[23].The lectinSambucus nigra
agglutinin (SNA)has apreference for 2–6 coupled sialic acids (Siaa2–
6Gal), which are present on A549 cells [24]. Interestingly, upon
treatment of cellswithLADANIA067 lectin bindingwasnot reduced
(Fig. 4A) indicating that the extract did not hinder the accessibility of
the receptor for IAV on the cell surface.
Since our data indicated an inhibitory effect of LADANAIA067
very early in the infection process, we further investigated whether
the compound directly interferes with the virus particle itself to
inhibit infection. In a hemagglutination inhibition (HI) assay
(Fig. 4B) we made use of the agglutinating feature of IAV towards
red blood cells (RBC). IAV-binding of the hemagglutinin provokes
crosslinking of RBC and will form a type of lattice in this case.
This results in a diffuse appearance of the RBC in a round-bottom
vial (Fig. 4B lanes 3 and 4) in contrast to a spot like appearance of
precipitated RBC in the absence of any virus or other
agglutinating agent (Fig. 4B lanes 1 and 2). We used the plant
extract CYSTUS052 as a control that already has previously been
shown to prevent binding of IAV to RBC [10]. Accordingly,
CYSTUS052 showed inhibition of RBC agglutination at concen-
trations of 250 mg/ml and 500 mg/ml (Fig. 4B right panel lanes 7
and 8). In contrast, LADANIA067 was not able to inhibit RBC
agglutination at all, arguing against physical interaction of the
extract ingredients with the virion that would prevent binding to
cells (Fig. 4B left panel lanes 7 and 8). Nonetheless, to further
confirm that IAV replication is inhibited at a very early stage of
infection by LADANIA067 treatment, we visualized IAV inter-
nalisation by detection of virion-associated matrix protein (M1),
the most abundant viral protein in IAV particles, in Western blot
analysis (Fig. 4C). This approach has been previously described to
be a quite selective assay to monitor virus uptake [25]. M1 protein
levels were reduced in LADANIA067 treated samples, indicating
inefficient viral uptake (Fig. 4C). This correlated well with reduced
progeny virus titers in cases of pre-treated virus samples (Fig. 3).
Thus, our results clearly indicate that LADANIA067 inhibits
virus internalisation, but at the same time does not interfere with
cellular viability, metabolism or transcription. Nonetheless, to
further assess whether LADANIA067 may provoke any other
pharmacological effect in cells, e.g. activation of intracellular
signalling events, we monitored the activation of different
signalling pathways upon stimulation with tumor necrosis factor
a (TNFa) or epidermal growth factor (EGF). The cytokine TNFa
is a strong activator of the cellular transcription factor NF-kB
(Fig. 4D, lanes 2, 4, 6). Activation of NF-kB was monitored in
Western blots by examination of degradation of IkBa, the
inhibitor of NF-kB (Fig. 4D, upper panel). In TNFa stimulated
cells IkBa was fully degraded, independent whether they were left
untreated or were pre-treated with LADANIA067 (Fig. 4D, upper
panel, lanes 5, 6) or CYSTUS052 (Fig. 4D, upper panel, lanes 3,
4). This indicates that LADANIA067 treatment neither activates
NF-kB nor inhibits receptor-mediated NF-kB activation. The
epidermal growth factor receptor (EGFR), a receptor tyrosine
kinase, is another important cellular signalling inducer, which has
also been identified to regulate IAV internalisation [24]. Thus, we
also monitored whether LADANIA067 may interfere with EGFR
signalling in the presence or absence of EGF. A549 cells were
treated with LADANIA067 or were left untreated (Fig. 4E) prior
to stimulation with EGF. We also included a reference extract in
these assays, CYSTUS052 that was previously shown to fail in
R. nigrum Possesses Anti-Influenza Virus Activity
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e63657
activating or inhibiting receptor-mediated signalling events [10].
EGF-mediated activation of EGFR and the downstream signalling
kinase ERK2 were monitored in Western blots with activation-
state specific anti-phospho-site antibodies. In these assays LADA-
NIA067, like CYSTUS052 failed to affect phosphorylation of
EGFR or ERK2, regardless whether the cells were pretreated with
one of the compounds or not. In summary, our results indicate
that cells are inert to LADANIA067 with respect to TNFa or
EGF-induced signalling responses. These results may stand as
general examples for cellular ligand/receptor systems. It was
already shown that IAV also activate the EGFR itself during initial
binding of IAV particles to cellular surfaces. If LADANIA067 is
able to block the interaction of IAV particles with host cells as
assumed, IAV induced EGFR activation should be suppressed.
Indeed, IAV induced EGFR activation was blocked in the
presence of LADANIA067 (Fig. 4F), verifying the interfering
function of LADANIA067 with virus particles itself that in turn
inhibits IAV internalisation into the host cells.
LADANIA067 does not Show any Tendency to Induce
Viral Resistance
Resistance to currently licenced anti-influenza drugs is an
increasing problem in clinical use. Thus, we explored whether
continuous LADANIA067 treatment would provoke emergence of
resistant variants in an established multi-passaging experiment.
The results revealed that LADANIA067 treatment did not result
in the development of resistant virus variants (Fig. 5). LADA-
NIA067 still efficiently blocked IAV propagation after the 5th to
7th passage when viral replication capacity in amantadine treated
cells was fully back to the untreated situation. In that respect
Figure 1. LADANIA067 impairs IAV replication. A549 cells were left untreated or treated with the indicated amounts of LADANIA067 before
and during infection with the influenza virus strains A/FPV/Bratislava/79 (FPV) (H7N7) (8 h: MOI = 0.1; 24 h: MOI = 0.01) (A), A/NRW/173/09, an
pandemic swine-origin-IAV (SO-IAV) (H1N1pan) (8 h: MOI = 1.5; 24 h: MOI = 0.5) (B) or A/Puerto Rico/8/34 (PR8) (H1N1) (MOI = 0.01) (C). In (C) cells
were left untreated or treated with the indicated amounts (left panel) or 50 mg/ml of LADANIA067 before and during infection. (A–C) The virus was
pretreated with LADANIA067 as well. Supernatants were assayed for progeny virus particles at the times indicated. Data represent means 6SD of 4
biological samples. Statistical significance was assessed by students t-test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0063657.g001
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Figure 2. LADANIA067 is not toxic or proapoptotic in A549 cells. (A) A549 cells were left untreated or treated with LADANIA067 with the
amounts and times as indicated. The impact of LADANIA067 on cell morphology was visualized by an Axiovert 2000 ApoTome microscope (100-fold
magnification) and monitored by photography. (B) A549 cells were left untreated or treated with 50 mg/ml, 100 mg/ml or 200 mg/ml LADANIA067 or
1 mM Staurosporine for the indicated time periods. Cell proliferation/viability was estimated via colorimetric assay that followed incubation of cells
with MTT. The proliferating cells are depicted, whereby the untreated controls were arbitrarily set as 100%. Data represent 6SD of twelve biological
samples. (C) A549 cell were transfected with a constitutive active CMV promoter luciferase plasmid. Eight hours post transfection cells were left
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LADANIA067 resembles the reference extract CYSTUS052 that
also blocked virus internalisation and did also not cause IAV
resistance in a similar experimental setting [10].
LADANIA067 Exhibits Antiviral Functions in vivo
Based on our results, LADANIA067 may be a promising source
for an antiviral agent that does not exhibit harmful side effects on
cell viability or metabolism and does not show any tendency to
induce resistant virus variants. Nonetheless, antiviral activity in
in vitro experiments may be different in vivo. Thus, we tested the
antiviral activity of LADANIA067 in vivo in BALB/c mice infected
with a sublethal dose of influenza virus A/FPV/Bratislava/79
(H7N7). With regard to cleavability of its hemagglutinin as a major
determinant of pathogenicity this strain belongs to highly
pathogenic avian influenza virus (HPAIV), a group also including
the H5N1 ‘‘bird-flu’’ viruses. Since the active ingredients of
LADANIA067 do not seem to be taken up to cells or get
metabolized, we favoured a topical rather than a systemic
treatment and therefore applied LADANIA067 directly into the
mouse lung as an aerosol. Four BALB/c mice were treated for
three (Fig. 6A) or five (Fig. 6C) consecutive days with 1.5 ml
LADANIA067 extract (10 mg/ml) twice a day using the
COAALA Mouse Aerosol Application System (Activaero GmbH).
As control four infected BALB/c mice were treated with the
untreated or treated with the indicated amounts of LADANIA067 or 10 mg/ml Cycloheximide respectively for 18 hours. Data represent 6SD of nine
biological samples and are given as the ratio of luciferase activity relative to the untreated control. (D) A549 cells were incubated in the presence and
absence of 50 mg/ml, 100 mg/ml or 200 mg/ml LADANIA for 24 h, 48 h and 72 h. A549 cells that were treated with Staurosporine (1 mg/ml) in
addition to EDTA (5 mM) for 4 hours served as control. Percentage of viable cells was measured by staining of dead cells with propidium iodide (PI) as
described in Materials and Methods. Data represent 6SD of nine biological samples. Statistical significance was assessed by students t-test (*p,0.05,
**p,0.01, ***p,0.001) (B, C, D). (E) A549 cells were left untreated or were treated with 1 mM Staurosporine for 8 h or 50 mg/ml or 100 mg/ml
LADANIA067 for 24 h or 48 h. Upon stimulation cell lysates were prepared and subjected to Western blot, and caspase mediated PARP cleavage was
determined as a measure for apoptosis induction. ERK2 expression was monitored as loading control.
doi:10.1371/journal.pone.0063657.g002
Figure 3. LADANIA067 inhibits IAV replication at early times of infection. (A) A549 cells were left untreated or treated with 100 mg/ml of
LADANIA067, which was added at the indicated times during infection with FPV (H7N7) (MOI = 1). (B-D) A549 cells and/or virus were left untreated or
treated with 100 mg/ml of LADANIA067 pre-infection or post-infection (p.i.). For infection FPV (H7N7) (MOI = 0.1), SO-IAV (H1N1pan) (MOI = 1) and PR8
(H1N1) (MOI = 5) have been used. Supernatants were assayed for progeny virus particles 8 h p.i. Data represent means 6SD of 4 biological samples
(A) or 6 biological samples (B–D). Statistical significance was assessed by students t-test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0063657.g003
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Figure 4. LADANIA067 inhibits viral internalisation. (A) A549 cells were left untreated or treated with 100 mg/ml LADANIA067 for 1 h at 37uC.
Biotinylated Sambucus nigra agglutinin (SNA) (1 mg/ml) was added and cells were incubated for 1 h at 4uC with A549 cells. Subsequently, cells were
incubated with Cy3-conjugated streptavidin to detect lectins for fluorescence microscopy using an Axiovert 2000 ApoTome microscope with
AxioCam digital camera and AxioVision software (Zeiss) (20-fold magnification) (B) LADANIA067 was diluted as indicated. Influenza A/FPV/Bratislava/
79 was diluted in PBS (46105 pfu/well) and 50 ml was added per well of a 96-well plate. After preincubation of 45 min, chicken erythrocytes (1:20 in
PBS) were mixed with the solution. In samples where viruses were preincubated with LADANIA067 or CYSTUS052, up to a certain dilution the virus
particles are no longer capable of agglutinating erythrocytes, indicating an interaction of LADANIA067 or CYSTUS052 with the viral HA. (C) A549 cells
(upper panel) or MDCK cells (lower panel) were left untreated or treated with 200 mg/ml LADANIA067 30 min before infection. Also the influenza
virus A/Puerto Rico/8/34 was left untreated or was incubated with the same amount of LADANIA067 at 4uC for 30 min. Subsequently cells were left
untreated or infected (MOI = 10) with virus for 30 min at 4uC till a temperature shift to 37uC for further 15 min. Upon stimulation cells were washed
twice with PBS and cell lysates were prepared and subjected to Western blot. Viral M1 protein was determined as a measure for attached and
internalized virus particles. A549 cells were left untreated or treated with 100 mg/ml LADANIA067 for 4 h prior to stimulation with (D) 5 ng/ml TNFa
for 20 min or (E) 30 ng/ml EGF for 10 min. (F) Influenza virus A/Puerto Rico/8/34 was left untreated or was incubated with the indicated amounts of
LADANIA067 supplemented with medium for 30 min at 4uC. Subsequently, cells were washed with PBS and incubated for 60 min at 37uC without
virus or with virus which was left untreated or was pretreated with LADANIA067. Upon stimulation cell lysates were prepared and subjected to
Western blot. (D) Expression of IkBa, (E, F) phosphorylation of EGFR and ERK2 were detected and (D, E, F) EGFR or ERK2 expression was monitored as
loading control.
doi:10.1371/journal.pone.0063657.g004
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solvent H2O. Reduction of virus titers in the lung of infected
animals was detectible at day three of infection (Fig. 6A, B). The
differences in virus accumulation in lungs correlated well with the
body weight of the animals (Fig. 6C). In comparison to H2O
treated IAV infected BALB/c mice showing a clear body weight
loss whereas LADANIA067 treated, did not show any body weight
reduction. In an additional in vivo experiment (Fig. 6B) eight
BALB/c mice per group were infected with recombinant influenza
virus A/Puerto Rico/8/34 (H1N1rec). Treatment for three
consecutive days with 1.5 ml LADANIA067 extract (15 mg/ml)
in comparison to the solvent H2O control twice a day using the
COAALA Mouse Aerosol Application System (Activaero GmbH),
resulted in significantly reduced viral lung titers upon LADA-
NIA067 treatment, verifying our former results.
Discussion
Infections with IAV are still major plagues worldwide with the
potential to cause devastating pandemics. The increasing frequen-
cies of viral resistance to the currently available antivirals that
exclusively target specific viral factors highlight the importance for
novel antiviral strategies. In the present study we demonstrate that
an extract derived from Ribes nigrum folium, LADANIA067, exerts a
potent antiviral activity in vitro and in vivo. On a molecular basis
the extract appears to interfere with the virus particle, preventing
virus internalisation. However, unlike the reference extract
CYSTUS052, LADANIA067 does not interfere with the viral
hemagglutinin, since viral agglutination of RBC was not affected
in the presence of antiviral concentrations of LADANIA067.
Furthermore, LADANIA067 does not directly interact with sialic
acids (SA), the cellular receptors of influenza viruses. Nonetheless,
an interaction with other cell surface components, such as proteins
and oligosaccharides can not be ruled out even if enhanced
binding to the cellular surface should have been impeded some of
the cellular functions examined or binding of ligands to the cell
surface, as analyzed in Fig. 4D, E.
An integral feature of LADANIA067 is the very high content in
polyphenols, including gallic acid and p-hydroxybenzoic acid [18].
Polyphenols bear protein-binding capacity, probably also physi-
cally interacting with pathogens and/or cellular surfaces in an
unspecific manner. In fact LADANIA067 seems to interfere with
the virus particles during virus internalisation as indicated by a
lack of IAV induced EGFR phosphorylation in the presence of
LADANIA067. Concomitantly signal induction during virus
internalisation is prevented resulting in reduced viral uptake into
the host cells. Another major evidence of an unspecific rather than
a specific interference of LADANIA067 with the virus particle
may be the reduced capability to develop resistant variants.
Additionally, polyphenols have been demonstrated to possess
Figure 5. LADANIA067 shows no tendency to induce virus drug
resistance. A549 cells were infected with FPV (MOI = 0.001) for 24 h
and left untreated or treated with 100 mg/ml of LADANIA067 or 5 mM
amantatine. Cells and virus were pre-incubated with LADANIA067 for
30 min and LADANIA067 has been added to the medium throughout
the infection. Amantadine was added to the medium upon virus
inoculation of the cells. The supernatants were taken and employed for
infection in the next round of investigation.
doi:10.1371/journal.pone.0063657.g005
Figure 6. LADANIA067 efficiently blocks influenza virus
propagation in vivo. (A, C) Four 8-week-old BALB/c mice per group
were intranasally infected with sublethal doses (A) 103 pfu or (C) 56102
pfu of FPV (H7N7). (B) Eight 8-week-old BALB/c mice per group were
intranasally infected with sublethal doses of recombinant PR8
(H1N1rec) (46102 pfu). Mice were either solvent or LADANIA067
treated (1.5 ml per mice, at a concentration of (A, C) 10 mg/ml or (B)
15 mg/ml) via inhalation, twice a day for (A, B) three days or (C) five
days. (A, B) Virus titers of infected lungs were determined 3 days p.i. in
standard plaque titrations. (C) Body weight of the infected mice was
monitored.
doi:10.1371/journal.pone.0063657.g006
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antibacterial activity as well, thus also acting against bacterial co-
infections, another threatening complication in severe influenza
virus infection [15]. Although to date the nature of the active
ingredient(s) of LADANIA067 is not known and, dependent on the
extraction method variations can occur [13,18], the identified
action profile points to the high polyphenol content as being
responsible for its antiviral activity.
LADANIA067 treatment did not result in negative effects on
cell proliferation, metabolism, transcriptional/translational activity
or the responsiveness of the cell to ligands. Especially the latter is
indicative of a missing pharmacological activity of LADANIA067,
which is probably due to the fact that the active ingredients of the
extract are not taken up to cells. However, this is also a
disadvantage with regard to treatment options, since LADA-
NIA067 has to be applied locally as an antiviral agent. In fact, our
first results indicate that LADANIA067 is a potent antiviral agent
in vivo, since aerosol treatment of infected mice protected these
animals from the disease.
Although LADANIA067 is not able to prevent RBC aggluti-
nation by IAV in comparison to CYSTUS052, several functional
similarities exist between the two compounds. Moreover, these
kinds of plant extracts may also be considered for prophylaxis.
Fruits, leaves and buds of this plant have been used for centuries in
traditional cuisine and even traditional medicine, without reports
of side effects or allergic reactions. Further, the emergency of
resistant virus variants is lowered due to a putative unspecific
interaction with the pathogens. Such an unspecific interaction with
the pathogen that prevents binding to cellular receptors greatly
rules out an induction of antiviral immune responses. This is in
contrast to viral interference with other receptor-mediated
processes, e.g. engagement of receptors of the proteinase-activated
receptor family (PAR) that act via enhancement of IFNc-
production [26,27,28].
In particular, the inhalable formulation of LADANIA067 shows
potential as a replacement or supplementary strategy to current
anti-influenza therapeutics.
Although the efficacy of LADANIA067 action in infected
individuals has still to be confirmed, this plant extract holds
promising antiviral effects and may serve as novel amply available
anti-influenza drug.
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